Paperonium

← Back to the plain-language case

Abstract and Discussion give near-loop median PFS as 11.1 months; Results and source data give 5.5

Nat Commun (2025) · doi:10.1038/s41467-025-61817-8 · PMC12460621

Summary

The paper's exploratory ZENITH20 analysis compares progression-free survival (PFS) under poziotinib between 63 patients with near-loop and 19 with far-loop EGFR exon 20 insertions. The abstract and the Discussion give the near-loop median PFS as 11.1 months (vs 3.5, p = 0.016). The Results paragraph that reports the Kaplan-Meier analysis (Fig. 5c) gives 5.5 months (vs 3.5, log-rank p = 0.015, HR 0.42, 95% CI 0.21-0.86). The paper's own patient-level Source Data reproduce the Results values exactly (5.45 vs 3.55 months, p = 0.0153, Cox HR 0.42, 0.21-0.86). The abstract values are reproduced exactly (11.14 vs 3.48 months, p = 0.0160) only when the progression/censoring indicator is reversed. The direction and significance of the near-loop advantage are unchanged, but the abstract roughly doubles the headline near-loop estimate and puts it close to the 12.0 months it reports for mobocertinib.

What the paper reports

All quotations were checked verbatim against the PMC-archived text with src/show.py.

Abstract:

Although the study’s primary efficacy endpoint was not met in the overall cohort, the exploratory analysis indicates poziotinib has superior benefit in EGFRex20 near- versus far-insertions showing greater mean tumor size reduction (-25.9% vs. -9.8%, p = 0.0014) and progression-free survival (PFS, 11.1 vs. 3.5 months, p = 0.016). In comparison, in the previously published EXCLAIM trial (NCT02716116), mobocertinib demonstrates similar activities across both groups in tumor size reduction (-38.5% vs. -34.1%, p = 0.59) and PFS (12.0 vs. 13.0 months, p = 0.99).

Results, section "Clinical response with poziotinib in near- vs. far- EGFRex20ins NSCLC", second paragraph:

In this cohort, 98 patients had at least one tumor measurement after poziotinib treatment, among those, 82 patients had exon 20 insertions location information per local next-generation sequencing (NGS) testing, with 63 (77%) patients whose tumor mutation were in the near-loop amino acids A767-P772 and 19 (23%) in the far-loop H773-C775 amino acids.

The median progression-free survival (PFS) was also significantly different in patients with near- vs far-loop insertions at 5.5 months (near) vs. 3.5 months (far) (Log Rank p = 0.015), with a PFS hazard ratio of 0.42 (near- vs. far- 95% Confidence Interval [CI] 0.21-0.86, Fig. 5c).

Results, same section, first paragraph (all treated patients):

Among the 17 responders, the median duration of response (DoR) was 7.4 months (95% CI, 3.7 to 9.7, Fig. 4b), and median progression-free survival (PFS) for all treated patients was 4.2 months (95% CI, 3.7 to 6.6).

Discussion, second paragraph:

In the ZENITH20 trial cohort 1, the clinical efficacy was limited in the total population, not meeting the previously defined efficacy endpoint, however, the near-loop insertions responded better to poziotinib both at tumor size reduction and at PFS (11.1 months [near] vs. 3.5 months [far]).

Methods, "Retrospective analysis of patient outcomes by mutation location":

progression-free survival (PFS), which was measured as time from the beginning of TKI treatment until radiologic progression or death

Methods, "Statistics and reproducibility":

Median PFS was determined using the Kaplan-Meier method. Hazard ratios and p-values were determined using GraphPad Prism software and the Mantel-Cox Log Rank method.

Fig. 5 legend, panel c:

c Kaplan-Meier plot of progression-free survival of patients with near loop and far loop mutants. The long-Rank Mantel-Cox approach was used to determine the p-value.

Supplementary Data 1 (MOESM3), column header in sheets "Near 64" and "Far 20":

Censor, 0=PD, 1=censor

What the paper's own numbers show

Method. The Source Data file (MOESM7, Fig 5.xlsx, sheet "Fig 5a-c") has one row per patient for the Fig. 5a-c analysis, with insertion location, best response, PFS in months and a PFS_status column. It has 63 near-loop and 19 far-loop rows, the same as the text. The sheet does not say which value of PFS_status marks progression, so I worked that out from two other sources in the paper's own files. (1) All 14 patients whose best response was progressive disease have PFS_status = 1. (2) Of the 75 patients who appear in both the Source Data and Supplementary Data 1, every one with PFS_status = 1 has "Censor" = 0 (= PD) in Supplementary Data 1, and every one with PFS_status = 0 has "Censor" = 1 (= censor), 51 and 24 patients respectively. Their PFS times are identical in the two files. So PFS_status = 1 is progression or death. With my own Kaplan-Meier and Mantel-Cox log-rank code and a one-covariate Cox model (Efron ties), I computed the near- vs far-loop medians, p-value and hazard ratio twice: once with PFS_status = 1 as the event, and once with the indicator reversed. Every number below is printed by recompute.py.txt, which downloads both files from the publisher.

Quantity Location Reported Recomputed from the paper's own numbers
Near-loop median PFS Abstract; Discussion 11.1 months 5.45 months with PFS_status = 1 as event (42 of 63 events); 11.14 months only with the indicator reversed (21 events)
Near-loop median PFS Results (Fig. 5c) 5.5 months 5.45 months
Far-loop median PFS Abstract; Results; Discussion 3.5 months 3.55 months (11 of 19 events); 3.48 months with the indicator reversed
Log-rank p, near vs far Abstract 0.016 0.0153; 0.0160 with the indicator reversed
Log-rank p, near vs far Results; Fig. 5c 0.015 0.0153
HR near vs far (95% CI) Results 0.42 (0.21-0.86) 0.42 (0.21-0.86), Cox with Efron ties; 0.35 (0.14-0.85) with the indicator reversed
Near-minus-far difference in medians Abstract/Discussion vs Results 7.6 vs 2.0 months 1.90 months; 7.66 with the indicator reversed
Gap between the two near-loop medians printed Abstract vs Results 11.1 vs 5.5 5.6 months; ratio 2.02
Pooled KM median, all 82 patients with known location not reported (all 115 treated: 4.2, 95% CI 3.7-6.6) n/a 4.99 months; 11.14 with the indicator reversed
Near-loop patients with PFS ≥ 12 months Fig. 5c number at risk n/a 5 of 63

Under the coding that matches Supplementary Data 1, the Source Data reproduce every Results value to the printed precision: both medians, the p-value, the hazard ratio and both CI limits. Reversing the indicator, so that censored patients are treated as progressing, reproduces both abstract and Discussion numbers to the printed precision (11.14 → 11.1, 3.48 → 3.5, 0.0160 → 0.016). It does not reproduce the reported hazard ratio. No other coding I tried reproduces 11.1. Under the reversed coding the pooled Kaplan-Meier median of all 82 patients is also 11.14 months, far outside the 95% CI of 3.7 to 6.6 months reported for all 115 treated patients. The pooled median under the documented coding is 4.99 months, inside that interval. The populations differ (82 patients with at least one tumor measurement and a known insertion location vs all 115 treated), so this comparison is a plausibility check only.

Figure

The abstract and Discussion give a near-loop median PFS of 11.1 months, the Results give 5.5 months for the same comparison

Figure 1. The two versions of the same ZENITH20 near- vs far-loop PFS comparison, as printed. Left: the abstract and Discussion (11.1 vs 3.5 months, p = 0.016; neither gives a hazard ratio). Right: the Results paragraph citing Fig. 5c (5.5 vs 3.5 months, log-rank p = 0.015, HR 0.42, 95% CI 0.21-0.86). The patient groups (63 near-loop, 19 far-loop) and the far-loop median are the same in all three places. The conflicting values are in orange.

Reported medians against medians recomputed from the Source Data under the documented coding and with the indicator reversed

Figure 2. Median PFS by insertion location, in months, on a linear axis starting at 0. Filled circles are near-loop medians, open squares far-loop medians. Orange rows are values printed in the paper; blue rows are recomputed by recompute.py.txt from the paper's Source Data (sheet "Fig 5a-c", 63 near-loop and 19 far-loop patients). The p-values and hazard ratios on the right are log-rank and Cox (Efron) estimates, near vs far. The bottom pair: with PFS_status = 1 as progression, the coding confirmed by Supplementary Data 1, the data reproduce the Results and Fig. 5c (5.45 vs 3.55 months, p = 0.0153, HR 0.42). The top pair: the abstract and Discussion values are reproduced only when censored and progressing patients are swapped (11.14 vs 3.48 months, p = 0.0160). That swap gives HR 0.35, not the reported 0.42.

Why it matters

Explanations considered

Status

Suggested correction

In the abstract, replace

progression-free survival (PFS, 11.1 vs. 3.5 months, p = 0.016)

with

progression-free survival (PFS, 5.5 vs. 3.5 months, p = 0.015)

and in the second paragraph of the Discussion, replace

(11.1 months [near] vs. 3.5 months [far])

with

(5.5 months [near] vs. 3.5 months [far])

These are the values in the Results, in Fig. 5c and in the Source Data under the coding that matches Supplementary Data 1. The authors may also wish to state that the hazard ratio of 0.42 comes from a Cox model, if that is how it was estimated. They may also wish to reconcile the patient lists of Supplementary Data 1 (64/20) and the Source Data (63/19), and the far-loop range given in the Results (H773-C775) and the Methods (H773-R776).